Department of Biochemistry and Molecular Biology, University of South Alabama, Mobile, Alabama, USA.
Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
J Biol Chem. 2021 Jan-Jun;296:100313. doi: 10.1016/j.jbc.2021.100313. Epub 2021 Jan 20.
Functional genomic approaches have facilitated the discovery of rare genetic disorders and improved efforts to decipher their underlying etiology. PPP2R5D-related disorder is an early childhood onset condition characterized by intellectual disability, hypotonia, autism-spectrum disorder, macrocephaly, and dysmorphic features. The disorder is caused by de novo single nucleotide changes in PPP2R5D, which generate heterozygous dominant missense variants. PPP2R5D is known to encode a B'-type (B'56δ) regulatory subunit of a PP2A-serine/threonine phosphatase. To help elucidate the molecular mechanisms altered in PPP2R5D-related disorder, we used a CRISPR-single-base editor to generate HEK-293 cells in which a single transition (c.1258G>A) was introduced into one allele, precisely recapitulating a clinically relevant E420K variant. Unbiased quantitative proteomic and phosphoproteomic analyses of endogenously expressed proteins revealed heterozygous-dominant changes in kinase/phosphatase signaling. These data combined with orthogonal validation studies revealed a previously unrecognized interaction of PPP2R5D with AKT in human cells, leading to constitutively active AKT-mTOR signaling, increased cell size, and uncoordinated cellular growth in E420K-variant cells. Rapamycin reduced cell size and dose-dependently reduced RPS6 phosphorylation in E420K-variant cells, suggesting that inhibition of mTOR1 can suppress both the observed RPS6 hyperphosphorylation and increased cell size. Together, our findings provide a deeper understanding of PPP2R5D and insight into how the E420K-variant alters signaling networks influenced by PPP2R5D. Our comprehensive approach, which combines precise genome editing, isobaric tandem mass tag labeling of peptides generated from endogenously expressed proteins, and concurrent liquid chromatography-mass spectrometry (LC-MS), also provides a roadmap that can be used to rapidly explore the etiologies of additional genetic disorders.
功能基因组学方法促进了罕见遗传疾病的发现,并有助于解析其潜在病因。PPP2R5D 相关性疾病是一种儿童期起病的疾病,其特征为智力障碍、肌张力低下、自闭症谱系障碍、大头畸形和发育异常。该疾病是由 PPP2R5D 中的从头单核苷酸变化引起的,这些变化产生杂合显性错义变异体。已知 PPP2R5D 编码 PP2A-丝氨酸/苏氨酸磷酸酶的 B'-型(B'56δ)调节亚基。为了帮助阐明 PPP2R5D 相关性疾病中改变的分子机制,我们使用 CRISPR-单碱基编辑器在 HEK-293 细胞中引入一个单转换(c.1258G>A)到一个等位基因中,精确模拟临床相关的 E420K 变体。对内源性表达蛋白进行无偏定量蛋白质组学和磷酸蛋白质组学分析显示激酶/磷酸酶信号的杂合显性变化。这些数据与正交验证研究相结合,揭示了 PPP2R5D 与人类细胞中 AKT 的先前未被认识的相互作用,导致 AKT-mTOR 信号的组成性激活、细胞体积增大和 E420K 变体细胞中不协调的细胞生长。雷帕霉素降低了 E420K 变体细胞的细胞大小,并呈剂量依赖性降低 RPS6 磷酸化,表明 mTOR1 的抑制可以抑制观察到的 RPS6 过度磷酸化和细胞体积增大。总之,我们的研究结果提供了对 PPP2R5D 的更深入了解,并深入了解 E420K 变体如何改变受 PPP2R5D 影响的信号网络。我们的综合方法,结合精确的基因组编辑、内源性表达蛋白产生的肽的同重标记串联质谱标签标记,以及同时进行的液相色谱-质谱(LC-MS),也为快速探索其他遗传疾病的病因提供了路线图。